Abata Therapeutics to Present at Upcoming Investor and Industry Events in June
31 May 2023
BOSTON--(BUSINESS WIRE)-- Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients living with severe autoimmune and inflammatory diseases, today announced that Samantha Singer, M.S., M.B.A., president, and chief executive officer will present at the following events in June:
Jefferies Global Healthcare Conference: Presentation on Wednesday, June 7, 2023, at 3:30 p.m. ET in New York, NY.
World Medical Innovation Forum: Panel discussion titled “The Innovation Gap: Old Dog, New Tricks – Reprogramming the Immune System” on Wednesday, June 14, 2023, at 9:15 a.m. ET in Boston, MA.
About Abata Therapeutics
Abata Therapeutics is focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases. Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable. AbataAbata’s lead program is in progressive multiple sclerosis (MS), and its second program is in type 1 diabetes - both indications are tissue-specific autoimmune diseases with substantial unmet needs, supporting a strong rationale for AbataAbata’s Treg approach. The company was launched in 2021 by Third Rock Ventures, with participation from a diverse syndicate of investors, including ElevateBio, Lightspeed Venture Partners, Invus, Samsara BioCapital, and the JDRF T1D Fund. Abata is based in Watertown, Mass. Please visit abatatx.com or follow us on Twitter or LinkedIn for more information.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.